Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	dopamine neurotransmitter receptor activity, coupled via Gi/Go	DRD2 DRD3	5.61e-05	3	87	2	GO:0001591
GeneOntologyMolecularFunction	pancreatic polypeptide receptor activity	NPY4R2 NPY4R	1.12e-04	4	87	2	GO:0001602
GeneOntologyMolecularFunction	dopamine neurotransmitter receptor activity	DRD2 DRD3	1.86e-04	5	87	2	GO:0004952
GeneOntologyMolecularFunction	voltage-gated sodium channel activity	SCN2A SCN5A SCN9A	1.93e-04	26	87	3	GO:0005248
GeneOntologyBiologicalProcess	response to histamine	DRD2 DRD3 HRH1	1.50e-05	12	86	3	GO:0034776
GeneOntologyBiologicalProcess	response to morphine	DRD2 DRD3 ADCY8	3.07e-05	15	86	3	GO:0043278
GeneOntologyBiologicalProcess	response to isoquinoline alkaloid	DRD2 DRD3 ADCY8	3.77e-05	16	86	3	GO:0014072
GeneOntologyBiologicalProcess	epithelial cell differentiation involved in kidney development	LHX1 ASXL1 AMPD2 EDNRA	4.38e-05	47	86	4	GO:0035850
GeneOntologyBiologicalProcess	positive regulation of cytokinesis	CUL3 DRD2 DRD3 CDC6	8.17e-05	55	86	4	GO:0032467
GeneOntologyBiologicalProcess	cell differentiation involved in kidney development	LHX1 ASXL1 AMPD2 EDNRA	9.40e-05	57	86	4	GO:0061005
GeneOntologyBiologicalProcess	podocyte differentiation	ASXL1 AMPD2 EDNRA	1.02e-04	22	86	3	GO:0072112
GeneOntologyBiologicalProcess	glomerular epithelial cell differentiation	ASXL1 AMPD2 EDNRA	1.02e-04	22	86	3	GO:0072311
GeneOntologyBiologicalProcess	renal filtration cell differentiation	ASXL1 AMPD2 EDNRA	1.02e-04	22	86	3	GO:0061318
GeneOntologyBiologicalProcess	negative regulation of dopamine receptor signaling pathway	DRD2 DRD3	1.03e-04	4	86	2	GO:0060160
GeneOntologyBiologicalProcess	glomerular epithelium development	ASXL1 AMPD2 EDNRA	1.17e-04	23	86	3	GO:0072010
GeneOntologyBiologicalProcess	nephron epithelium development	LHX1 ASXL1 AMPD2 KIF26B EDNRA	1.98e-04	128	86	5	GO:0072009
GeneOntologyBiologicalProcess	phospholipase C-activating G protein-coupled receptor signaling pathway	DRD2 DRD3 TRPC1 HRH1 EDNRA	2.37e-04	133	86	5	GO:0007200
GeneOntologyBiologicalProcess	adenylate cyclase-inhibiting dopamine receptor signaling pathway	DRD2 DRD3	2.55e-04	6	86	2	GO:0007195
GeneOntologyCellularComponent	voltage-gated sodium channel complex	SCN2A SCN5A SCN9A	4.38e-05	17	86	3	GO:0001518
GeneOntologyCellularComponent	sodium channel complex	SCN2A SCN5A SCN9A	2.27e-04	29	86	3	GO:0034706
MousePheno	abnormal nervous system electrophysiology	CUL3 PTCHD1 DRD2 TRPC1 SCN2A SBF2 SCN5A SCN9A STMN2 TAFA4 PDE10A ADCY8	3.11e-08	329	65	12	MP:0002272
MousePheno	abnormal single cell response	PTCHD1 DRD2 TRPC1 SCN9A ADCY8	5.42e-07	35	65	5	MP:0003463
MousePheno	abnormal action potential	SCN2A SBF2 SCN5A SCN9A STMN2 TAFA4 PDE10A	2.65e-06	133	65	7	MP:0005402
Domain	ARM-type_fold	SMG1 ATR COPG1 XPO6 IFT172 EIF4G1 ASPM TAF2 ARMH3 HEATR3 ARMC8	3.86e-07	339	85	11	IPR016024
Domain	Na_trans_cytopl	SCN2A SCN5A SCN9A	1.80e-06	6	85	3	PF11933
Domain	Na_trans_cytopl	SCN2A SCN5A SCN9A	1.80e-06	6	85	3	IPR024583
Domain	Na_channel_asu	SCN2A SCN5A SCN9A	1.07e-05	10	85	3	IPR001696
Domain	Na_trans_assoc	SCN2A SCN5A SCN9A	1.07e-05	10	85	3	IPR010526
Domain	Na_trans_assoc	SCN2A SCN5A SCN9A	1.07e-05	10	85	3	PF06512
Domain	HEAT_REPEAT	SMG1 ATR COPG1 HEATR3 ARMC8	1.66e-05	70	85	5	PS50077
Domain	NPY4_rcpt	NPY4R2 NPY4R	2.05e-05	2	85	2	IPR001933
Domain	Dopamine_rcpt	DRD2 DRD3	2.03e-04	5	85	2	IPR000929
Domain	FATC	SMG1 ATR	2.03e-04	5	85	2	PF02260
Domain	ARM-like	SMG1 ATR COPG1 XPO6 ASPM HEATR3 ARMC8	2.31e-04	270	85	7	IPR011989
Domain	FAT	SMG1 ATR	3.03e-04	6	85	2	PS51189
Domain	FATC	SMG1 ATR	3.03e-04	6	85	2	PS51190
Domain	FATC_dom	SMG1 ATR	3.03e-04	6	85	2	IPR003152
Domain	PIK_FAT	SMG1 ATR	3.03e-04	6	85	2	IPR014009
Domain	FATC	SMG1 ATR	3.03e-04	6	85	2	SM01343
Domain	IQ	SCN2A SCN5A SCN9A ASPM	5.09e-04	81	85	4	SM00015
Domain	-	ATR COPG1 XPO6 ASPM HEATR3 ARMC8	5.28e-04	222	85	6	1.25.10.10
Domain	NPY_rcpt	NPY4R2 NPY4R	7.22e-04	9	85	2	IPR000611
Domain	IQ_motif_EF-hand-BS	SCN2A SCN5A SCN9A ASPM	7.58e-04	90	85	4	IPR000048
Domain	IQ	SCN2A SCN5A SCN9A ASPM	8.57e-04	93	85	4	PS50096
Domain	7TM_GPCR_Srsx	DRD2 DRD3 MC5R HRH1	1.71e-03	112	85	4	SM01381
Domain	Myotubularin-like_Pase_dom	MTMR12 SBF2	1.80e-03	14	85	2	IPR010569
Domain	PPASE_MYOTUBULARIN	MTMR12 SBF2	1.80e-03	14	85	2	PS51339
Domain	Myotubularin_fam	MTMR12 SBF2	1.80e-03	14	85	2	IPR030564
Domain	Myotub-related	MTMR12 SBF2	1.80e-03	14	85	2	PF06602
Domain	Ion_trans_dom	TRPC1 SCN2A SCN5A SCN9A	1.82e-03	114	85	4	IPR005821
Domain	Ion_trans	TRPC1 SCN2A SCN5A SCN9A	1.82e-03	114	85	4	PF00520
Domain	PI3/4_kinase_CS	SMG1 ATR	2.07e-03	15	85	2	IPR018936
Domain	Channel_four-helix_dom	SCN2A SCN5A SCN9A	2.23e-03	57	85	3	IPR027359
Domain	-	SCN2A SCN5A SCN9A	2.23e-03	57	85	3	1.20.120.350
Domain	-	SMG1 ATR	2.36e-03	16	85	2	1.10.1070.11
Domain	PI3Kc	SMG1 ATR	2.36e-03	16	85	2	SM00146
Domain	PI3/4_kinase_cat_dom	SMG1 ATR	2.99e-03	18	85	2	IPR000403
Domain	PI3_PI4_kinase	SMG1 ATR	2.99e-03	18	85	2	PF00454
Domain	PI3_4_KINASE_3	SMG1 ATR	2.99e-03	18	85	2	PS50290
Domain	PI3_4_KINASE_1	SMG1 ATR	2.99e-03	18	85	2	PS00915
Domain	PI3_4_KINASE_2	SMG1 ATR	2.99e-03	18	85	2	PS00916
Domain	DAPIN	NLRP9 NLRP8	4.46e-03	22	85	2	PS50824
Domain	PYRIN	NLRP9 NLRP8	4.46e-03	22	85	2	PF02758
Domain	DAPIN	NLRP9 NLRP8	4.46e-03	22	85	2	IPR004020
Domain	PYRIN	NLRP9 NLRP8	4.46e-03	22	85	2	SM01289
Domain	NACHT	NLRP9 NLRP8	4.87e-03	23	85	2	PS50837
Domain	NACHT_NTPase	NLRP9 NLRP8	4.87e-03	23	85	2	IPR007111
Pathway	WP_GPCRS_CLASS_A_RHODOPSINLIKE	DRD2 DRD3 NPY4R MC5R HRH1 GPR45 EDNRA	7.18e-05	260	56	7	M39397
Pathway	REACTOME_DOPAMINE_RECEPTORS	DRD2 DRD3	1.54e-04	5	56	2	M27301
Pathway	REACTOME_DOPAMINE_RECEPTORS	DRD2 DRD3	1.54e-04	5	56	2	MM15007
Pathway	REACTOME_SIGNALING_BY_GPCR	DRD2 DRD3 NPY4R MC5R HRH1 CCL20 PDE10A ADCY8 GPR45 EDNRA	2.01e-04	646	56	10	MM14962
Pathway	REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS	SCN2A SCN5A SCN9A	2.47e-04	31	56	3	M877
Pathway	WP_MONOAMINE_GPCRS	DRD2 DRD3 HRH1	2.47e-04	31	56	3	MM15871
Pathway	REACTOME_PHASE_0_RAPID_DEPOLARISATION	SCN2A SCN5A SCN9A	2.71e-04	32	56	3	M27455
Pathway	WP_MONOAMINE_GPCRS	DRD2 DRD3 HRH1	2.98e-04	33	56	3	M39585
Pathway	REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS	DRD2 DRD3 NPY4R MC5R HRH1 CCL20 EDNRA	3.13e-04	330	56	7	M18334
Pathway	REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS	DRD2 DRD3 NPY4R MC5R HRH1 CCL20 EDNRA	3.31e-04	333	56	7	MM14963
Pathway	REACTOME_SIGNALING_BY_GPCR	DRD2 DRD3 NPY4R MC5R HRH1 CCL20 PDE10A ADCY8 GPR45 EDNRA	3.91e-04	702	56	10	M746
Pathway	REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS	ATR CDC6 RFC3	4.19e-04	37	56	3	M11153
Pathway	REACTOME_RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS	GAPVD1 RAB3GAP2 SBF2 CHM	4.43e-04	90	56	4	M27779
Pathway	REACTOME_RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS	GAPVD1 RAB3GAP2 SBF2 CHM	4.62e-04	91	56	4	MM15518
Pathway	PID_ATR_PATHWAY	ATR CDC6 RFC3	4.90e-04	39	56	3	M46
Pathway	REACTOME_AMINE_LIGAND_BINDING_RECEPTORS	DRD2 DRD3 HRH1	6.11e-04	42	56	3	M5868
Pathway	REACTOME_AMINE_LIGAND_BINDING_RECEPTORS	DRD2 DRD3 HRH1	6.11e-04	42	56	3	MM14971
Pathway	WP_GPCRS_NONODORANT	DRD2 DRD3 NPY4R MC5R HRH1 EDNRA	6.28e-04	266	56	6	MM15843
Pathway	KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION	DRD2 DRD3 NPY4R MC5R HRH1 EDNRA	7.06e-04	272	56	6	M13380
Pathway	WP_GPCRS_CLASS_A_RHODOPSINLIKE	DRD3 NPY4R MC5R HRH1 GPR45	8.39e-04	186	56	5	MM15994
Pubmed	International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels.	SCN2A SCN5A SCN9A	1.26e-06	9	87	3	16382098
Pubmed	Regulation of neuronal voltage-gated sodium channels by the ubiquitin-protein ligases Nedd4 and Nedd4-2.	SCN2A SCN5A SCN9A	4.25e-06	13	87	3	15123669
Pubmed	Dissociation of heterotrimeric g proteins in cells.	DRD2 DRD3 NPY4R HRH1 CCL20 EDNRA	6.11e-06	179	87	6	18577758
Pubmed	Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation.	ATR CDC6	6.19e-06	2	87	2	22179839
Pubmed	Striatal dopamine D2/3 receptor availability increases after long-term bariatric surgery-induced weight loss.	DRD2 DRD3	6.19e-06	2	87	2	27184782
Pubmed	N-linked Glycosylation on the N-terminus of the dopamine D2 and D3 receptors determines receptor association with specific microdomains in the plasma membrane.	DRD2 DRD3	6.19e-06	2	87	2	25289757
Pubmed	Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression.	DRD2 DRD3	6.19e-06	2	87	2	12834818
Pubmed	Mapping the landscape of human dopamine D2/3 receptors with [11C]raclopride.	DRD2 DRD3	6.19e-06	2	87	2	31444615
Pubmed	Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.	DRD2 DRD3	6.19e-06	2	87	2	23154100
Pubmed	Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.	DRD2 DRD3	6.19e-06	2	87	2	22970199
Pubmed	Association of novelty seeking scores and striatal dopamine D₂/D₃ receptor availability of healthy volunteers: single photon emission computed tomography with ¹²³i-iodobenzamide.	DRD2 DRD3	6.19e-06	2	87	2	20970071
Pubmed	Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models.	DRD2 DRD3	6.19e-06	2	87	2	32083297
Pubmed	ATR (AT mutated Rad3 related) activity stabilizes Cdc6 and delays G2/M-phase entry during hydroxyurea-induced S-phase arrest of HeLa cells.	ATR CDC6	6.19e-06	2	87	2	19154794
Pubmed	Posterior dopamine D2/3 receptors and brain network functional connectivity.	DRD2 DRD3	6.19e-06	2	87	2	28700819
Pubmed	Decreased c-fos responses to dopamine D(1) receptor agonist stimulation in mice deficient for D(3) receptors.	DRD2 DRD3	6.19e-06	2	87	2	10506202
Pubmed	DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder.	DRD2 DRD3	6.19e-06	2	87	2	23683269
Pubmed	Palmitoylation on the carboxyl terminus tail is required for the selective regulation of dopamine D2 versus D3 receptors.	DRD2 DRD3	6.19e-06	2	87	2	27349735
Pubmed	Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.	DRD2 DRD3	6.19e-06	2	87	2	19302829
Pubmed	Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study.	DRD2 DRD3	6.19e-06	2	87	2	19457373
Pubmed	Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D₂and D₃ receptors.	DRD2 DRD3	6.19e-06	2	87	2	20952497
Pubmed	G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.	DRD2 DRD3	6.19e-06	2	87	2	18218829
Pubmed	Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.	DRD2 DRD3	6.19e-06	2	87	2	18410503
Pubmed	Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.	DRD2 DRD3	6.19e-06	2	87	2	11425949
Pubmed	Cortical dopamine D2/D3 receptors and verbal memory in man.	DRD2 DRD3	6.19e-06	2	87	2	20188195
Pubmed	Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.	DRD2 DRD3	6.19e-06	2	87	2	25511804
Pubmed	Dopamine D2 receptors preferentially regulate the development of light responses of the inner retina.	DRD2 DRD3	6.19e-06	2	87	2	25393815
Pubmed	The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.	DRD2 DRD3	6.19e-06	2	87	2	18987627
Pubmed	Roles of conserved intracellular sequences regions for the proper expression of dopamine D(2) and D(3) receptors.	DRD2 DRD3	6.19e-06	2	87	2	18481021
Pubmed	The candidate gene approach in alcoholism: are there gender-specific differences?	DRD2 DRD3	6.19e-06	2	87	2	14628173
Pubmed	Kinetic Analysis of Membrane Potential Dye Response to NaV1.7 Channel Activation Identifies Antagonists with Pharmacological Selectivity against NaV1.5.	SCN5A SCN9A	6.19e-06	2	87	2	26861708
Pubmed	Cyr61/CCN1 induces CCL20 production by keratinocyte via activating p38 and JNK/AP-1 pathway in psoriasis.	CCN1 CCL20	6.19e-06	2	87	2	28602508
Pubmed	Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase.	DRD2 DRD3	6.19e-06	2	87	2	15102843
Pubmed	DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis.	DRD2 DRD3	6.19e-06	2	87	2	31538542
Pubmed	Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity.	DRD2 DRD3	6.19e-06	2	87	2	22776462
Pubmed	Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans.	DRD2 DRD3	6.19e-06	2	87	2	26944295
Pubmed	Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.	DRD2 DRD3	6.19e-06	2	87	2	16959057
Pubmed	Fluorescent ligands for dopamine D2/D3 receptors.	DRD2 DRD3	6.19e-06	2	87	2	33318558
Pubmed	[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region.	DRD2 DRD3	6.19e-06	2	87	2	17175177
Pubmed	Dopamine Receptor Signaling in MIN6 β-Cells Revealed by Fluorescence Fluctuation Spectroscopy.	DRD2 DRD3	6.19e-06	2	87	2	27508444
Pubmed	Dopamine D2 (DAD2) and dopamine D3 (DAD3) receptor gene polymorphisms and treatment outcome in alcohol dependence.	DRD2 DRD3	6.19e-06	2	87	2	12811641
Pubmed	Effects of smoking on D₂/D₃ striatal receptor availability in alcoholics and social drinkers.	DRD2 DRD3	6.19e-06	2	87	2	23649848
Pubmed	Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells.	DRD2 DRD3	6.19e-06	2	87	2	8666994
Pubmed	Distinct genetic patterns of shared and unique genes across four neurodevelopmental disorders.	STXBP1 SCN2A	6.19e-06	2	87	2	32929885
Pubmed	[11 C]raclopride positron emission tomography study of dopamine-D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects.	DRD2 DRD3	6.19e-06	2	87	2	31943514
Pubmed	Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment.	DRD2 DRD3	6.19e-06	2	87	2	39187246
Pubmed	Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.	DRD2 DRD3	6.19e-06	2	87	2	27379794
Pubmed	Dopamine D2/3 Binding Potential Modulates Neural Signatures of Working Memory in a Load-Dependent Fashion.	DRD2 DRD3	6.19e-06	2	87	2	30478031
Pubmed	Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.	DRD2 DRD3	6.19e-06	2	87	2	22591910
Pubmed	Association study of dopamine D2 and D3 receptor gene polymorphisms with cocaine dependence.	DRD2 DRD3	6.19e-06	2	87	2	16094250
Pubmed	In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.	DRD2 DRD3	6.19e-06	2	87	2	22234337
Pubmed	Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients.	DRD2 DRD3	6.19e-06	2	87	2	12740603
Pubmed	Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).	DRD2 DRD3	6.19e-06	2	87	2	19011428
Pubmed	Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.	DRD2 DRD3	6.19e-06	2	87	2	27779245
Pubmed	No association of dopamine receptor sensitivity in vivo with genetic predisposition for alcoholism and DRD2/DRD3 gene polymorphisms in alcohol dependence.	DRD2 DRD3	6.19e-06	2	87	2	16759339
Pubmed	-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population.	DRD2 DRD3	6.19e-06	2	87	2	18496209
Pubmed	Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention.	DRD2 DRD3	6.19e-06	2	87	2	15537671
Pubmed	Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.	DRD2 DRD3	6.19e-06	2	87	2	21663922
Pubmed	Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.	DRD2 DRD3	6.19e-06	2	87	2	26819282
Pubmed	The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain.	DRD2 DRD3	6.19e-06	2	87	2	8313980
Pubmed	Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.	DRD2 DRD3	6.19e-06	2	87	2	19396436
Pubmed	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain.	DRD2 DRD3	6.19e-06	2	87	2	32818617
Pubmed	The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.	DRD2 DRD3	6.19e-06	2	87	2	29337986
Pubmed	Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain.	DRD2 DRD3	6.19e-06	2	87	2	22573693
Pubmed	Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity.	DRD2 DRD3	6.19e-06	2	87	2	24785761
Pubmed	New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion.	DRD2 DRD3	6.19e-06	2	87	2	30626912
Pubmed	Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors.	DRD2 DRD3	6.19e-06	2	87	2	10391470
Pubmed	D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia.	DRD2 DRD3	6.19e-06	2	87	2	28576546
Pubmed	Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.	DRD2 DRD3	6.19e-06	2	87	2	19669131
Pubmed	Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans.	DRD2 DRD3	6.19e-06	2	87	2	23954846
Pubmed	Cigarette Use and Striatal Dopamine D2/3 Receptors: Possible Role in the Link between Smoking and Nicotine Dependence.	DRD2 DRD3	6.19e-06	2	87	2	27634830
Pubmed	Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease.	DRD2 DRD3	6.19e-06	2	87	2	33039854
Pubmed	Latent-Profile Analysis Reveals Behavioral and Brain Correlates of Dopamine-Cognition Associations.	DRD2 DRD3	6.19e-06	2	87	2	29028935
Pubmed	Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice.	DRD2 DRD3	6.19e-06	2	87	2	11864730
Pubmed	A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [(11)C](+)PHNO.	DRD2 DRD3	6.19e-06	2	87	2	26164205
Pubmed	Dopamine D2/D3 receptor stimulation fails to promote dopaminergic neurogenesis of murine and human midbrain-derived neural precursor cells in vitro.	DRD2 DRD3	6.19e-06	2	87	2	17784836
Pubmed	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders.	DRD2 DRD3	6.19e-06	2	87	2	11857579
Pubmed	Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [11C]-(+)-PHNO study.	DRD2 DRD3	6.19e-06	2	87	2	34349232
Pubmed	Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.	DRD2 DRD3	6.19e-06	2	87	2	22291025
Pubmed	Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating.	SCN2A SCN5A	6.19e-06	2	87	2	16847056
Pubmed	Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients.	DRD2 DRD3	6.19e-06	2	87	2	22338593
Pubmed	[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.	DRD2 DRD3	6.19e-06	2	87	2	25641350
Pubmed	Postnatal ontogeny of dopamine D3 receptors in the mouse brain: autoradiographic evidence for a transient cortical expression.	DRD2 DRD3	6.19e-06	2	87	2	8836575
Pubmed	A shared spatial topography links the functional connectome correlates of cocaine use disorder and dopamine D2/3 receptor densities.	DRD2 DRD3	6.19e-06	2	87	2	39300138
Pubmed	Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.	DRD2 DRD3	6.19e-06	2	87	2	19217026
Pubmed	Early expression of D3 dopamine receptors in murine embryonic development.	DRD2 DRD3	6.19e-06	2	87	2	8601467
Pubmed	Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum.	DRD2 DRD3	1.85e-05	3	87	2	18644790
Pubmed	Voltage-gated sodium channels in taste bud cells.	SCN2A SCN9A	1.85e-05	3	87	2	19284629
Pubmed	Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects.	DRD2 DRD3	1.85e-05	3	87	2	20452395
Pubmed	Association of dopamine D(3) receptors with actin-binding protein 280 (ABP-280).	DRD2 DRD3	1.85e-05	3	87	2	11911837
Pubmed	Ependyma-expressed CCN1 restricts the size of the neural stem cell pool in the adult ventricular-subventricular zone.	CCN1 FOXJ1	1.85e-05	3	87	2	32009252
Pubmed	Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.	DRD2 DRD3	1.85e-05	3	87	2	30103286
Pubmed	Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography.	DRD2 DRD3	1.85e-05	3	87	2	12781734
Pubmed	DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents.	DRD2 DRD3	1.85e-05	3	87	2	18351593
Pubmed	Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors.	DRD2 DRD3	1.85e-05	3	87	2	7566118
Pubmed	Association study of dopamine receptor genes polymorphisms with the risk of schizophrenia in the Han Chinese population.	DRD2 DRD3	1.85e-05	3	87	2	27591410
Pubmed	Calmodulin mediates Ca2+ sensitivity of sodium channels.	SCN2A SCN5A	1.85e-05	3	87	2	15316014
Pubmed	Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor.	DRD2 DRD3	1.85e-05	3	87	2	15016423
Pubmed	Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia.	DRD2 DRD3	1.85e-05	3	87	2	29791666
Pubmed	Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors.	DRD2 DRD3	1.85e-05	3	87	2	9354330
Pubmed	The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis.	DRD2 DRD3	1.85e-05	3	87	2	26561806
Cytoband	19q13.42	ZNF765 ZNF845 NLRP9 ZNF813	9.79e-05	125	87	4	19q13.42
Cytoband	10q11.2	NPY4R ALOX5	3.18e-04	14	87	2	10q11.2
Cytoband	19q13.41	ZNF320 ZNF28 ZNF888	4.51e-04	78	87	3	19q13.41
Cytoband	Ensembl 112 genes in cytogenetic band chr19q13	ZNF765 ZNF845 NLRP9 ZNF320 ZNF28 ZNF813 ZNF888 NLRP8	1.93e-03	1192	87	8	chr19q13
GeneFamily	Sodium voltage-gated channel alpha subunits	SCN2A SCN5A SCN9A	2.46e-06	9	57	3	1203
GeneFamily	Dopamine receptors	DRD2 DRD3	9.71e-05	5	57	2	181
GeneFamily	Myotubularins\|Phosphoinositide phosphatases	MTMR12 SBF2	9.99e-04	15	57	2	903
GeneFamily	NLR family	NLRP9 NLRP8	2.80e-03	25	57	2	666
GeneFamily	Pyrin domain containing\|Pyrin and HIN domain family	NLRP9 NLRP8	2.80e-03	25	57	2	994
CoexpressionAtlas	DevelopingGonad_P2_epididymis_emap-30199_top-relative-expression-ranked_200	LHX1 EIF4G1 CHM ADCY8 EDNRA DMXL1	3.75e-05	157	84	6	gudmap_developingGonad_P2_epididymis_200
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_top-relative-expression-ranked_200	INHBB EIF4G1 ASPM CHM EDNRA DMXL1	4.03e-05	159	84	6	gudmap_developingGonad_e12.5_epididymis_200
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#2_top-relative-expression-ranked_200	EIF4G1 ASPM CHM EDNRA	1.00e-04	61	84	4	gudmap_developingGonad_e12.5_epididymis_k2_200
CoexpressionAtlas	DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#3_top-relative-expression-ranked_1000	SMG1 GAPVD1 EIF4G1 ASPM PDE10A CHM DMXL1	1.10e-04	275	84	7	gudmap_developingGonad_e14.5_ epididymis_1000_k3
CoexpressionAtlas	DevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#2_top-relative-expression-ranked_200	EIF4G1 CHM EDNRA DMXL1	1.28e-04	65	84	4	gudmap_developingGonad_e12.5_ovary_k2_200
CoexpressionAtlas	DevelopingKidney_e15.5_Podocyte cells_emap-27915_k-means-cluster#4_top-relative-expression-ranked_1000	LHX1 RNF150 CTNNAL1 CCN1 KIF26B TAF2 AQR	1.62e-04	293	84	7	gudmap_developingKidney_e15.5_Podocyte cells_1000_k4
CoexpressionAtlas	DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_500	LHX1 SMG1 EIF4G1 ASPM PDE10A CHM EDNRA DMXL1	2.30e-04	413	84	8	gudmap_developingGonad_e14.5_ epididymis_500
CoexpressionAtlas	DevelopingKidney_e13.5_podocyte cells_emap-27773_k-means-cluster#1_top-relative-expression-ranked_500	NOL4 RNF150 INHBB SCN2A AQR	2.52e-04	142	84	5	gudmap_developingKidney_e13.5_podocyte cells_500_k1
CoexpressionAtlas	dev gonad_e13.5_F_MeioticGermCell_Oct_top-relative-expression-ranked_200	ZNF845 ATR TRPC1 CCDC150 CCNB1IP1	2.60e-04	143	84	5	gudmap_dev gonad_e13.5_F_MeioticGermCell_Oct_200
CoexpressionAtlas	DevelopingGonad_e14.5_ ovary_emap-6699_k-means-cluster#3_top-relative-expression-ranked_1000	SMG1 GAPVD1 EIF4G1 PDE10A CHM EDNRA	2.70e-04	225	84	6	gudmap_developingGonad_e14.5_ ovary_1000_k3
CoexpressionAtlas	DevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000	JAK1 LHX1 SMG1 RGS7BP EIF4G1 ASPM STMN2 CHM ADCY8 EDNRA DMXL1	3.04e-04	799	84	11	gudmap_developingGonad_e18.5_epididymis_1000
CoexpressionAtlas	DevelopingGonad_e16.5_ovary_emap-9563_k-means-cluster#2_top-relative-expression-ranked_1000	SMG1 GAPVD1 EIF4G1 ASPM CHM EDNRA	3.04e-04	230	84	6	gudmap_developingGonad_e16.5_ovary_1000_k2
CoexpressionAtlas	DevelopingKidney_e13.5_podocyte cells_emap-27773_top-relative-expression-ranked_500	LHX1 NOL4 RNF150 INHBB KIF26B SCN2A DKK2 AQR	3.06e-04	431	84	8	gudmap_developingKidney_e13.5_podocyte cells_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_k-means-cluster#1_top-relative-expression-ranked_500	JAK1 SMG1 EIF4G1 ASPM ATP13A3 TAF2	3.11e-04	231	84	6	gudmap_developingLowerUrinaryTract_e14.5_ bladder_500_k1
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#5_top-relative-expression-ranked_500	EIF4G1 ASPM CHM EDNRA DMXL1	3.24e-04	150	84	5	gudmap_developingGonad_e12.5_epididymis_k5_500
CoexpressionAtlas	DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_100	EIF4G1 CHM EDNRA DMXL1	3.46e-04	84	84	4	gudmap_developingGonad_e14.5_ epididymis_100
ToppCell	Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	STXBP1 IL1RAPL2 KIF26B SCN2A SCN9A STMN2 CYP4X1	8.76e-08	188	87	7	b73e8a40393c3f656e2fcfe395a761b1f985c254
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SAT1 KIF26B SCN9A ASPM MC5R TAFA4 ADCY8	1.01e-07	192	87	7	0003d7ef9a8e521e70ac33c63aad843d9b6215c2
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Neuronal-interneuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LHX1 PTCHD1 STXBP1 KIF26B SCN2A STMN2	1.82e-06	187	87	6	1b2fdbfb1ce3f19795dfc4b1da5a94f4b057ec41
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	INHBB KIF26B TAFA4 ADCY8 DKK2 EDNRA	2.05e-06	191	87	6	9c0ee270209b02043393416ecc9a81ddedfbb8b6
ToppCell	Control-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	CTNNAL1 HRH1 ATP13A3 PDE10A RFC3 DKK2	2.12e-06	192	87	6	7e89b9125e8b85f6be85eeccef5c8644647ab0e1
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SAT1 KIF26B SCN9A ASPM TAFA4 ADCY8	2.18e-06	193	87	6	c4b22b62f3cc7bf0ec0eba76e1504c236290bbc9
ToppCell	Control-Myeloid\|Control / Disease state, Lineage and Cell class	CYRIA FBP1 SAT1 SBF2 ATP13A3 ALOX5	2.31e-06	195	87	6	46ce2e403ca5d757e5ba17349b6c7ce5cde1f195
ToppCell	facs-Lung-Endomucin-24m-Endothelial-Artery_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ASPM STMN2 ATP13A3 C12orf60 SLC12A7	3.70e-06	119	87	5	c3f1223356e7f245a460ea5568a223e34e458dc1
ToppCell	TCGA-Uterus-Primary_Tumor-Uterine_Carcinoma-Uterine_Carcinosarcoma\|TCGA-Uterus / Sample_Type by Project: Shred V9	CUL3 ZNF320 ZNF28 SAT1 ZNF888	1.18e-05	151	87	5	2810bfa01bd3016aeba29735eb4a9284792e8aac
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NOL4 PTCHD1 SCN2A STMN2 RFX6	1.51e-05	159	87	5	7747cef94c55144fddcd024a7495318357f1351b
ToppCell	10x5'-GI_large-bowel-Lymphocytic_T_CD8-Tem/emra_CD8\|GI_large-bowel / Manually curated celltypes from each tissue	NOL4 STXBP1 STMN2 RFX6 HEATR3	1.86e-05	166	87	5	13bef304ea3df8e8d2bc376a3287c78220a1b0c6
ToppCell	CD8+_Memory_T_cell-FLU-3\|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster	TRPC1 CCDC150 CCL20 CDC6 RFC3	2.21e-05	172	87	5	45ac433dbb3796f69e886c04457b2971403050ee
ToppCell	E16.5-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SAT1 STMN2 ATP13A3 GPR45 DKK2	2.47e-05	176	87	5	77516048aefbe1f48e825052756df0c310c1c486
ToppCell	E16.5-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SAT1 STMN2 ATP13A3 GPR45 DKK2	2.47e-05	176	87	5	96779273b94345250cf53ba671203345b43d9e00
ToppCell	368C-Myeloid-Macrophage-SPP1+_Macrophage_3\|368C / Donor, Lineage, Cell class and subclass (all cells)	ZNF845 GAPVD1 ZNF320 XPO6 CCDC150	2.60e-05	178	87	5	536a601abcc60867949ea06e9aafb6c7b799b56b
ToppCell	droplet-Lung-LUNG-30m-Mesenchymal-pericyte_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RNF150 TRPC1 SCN5A ADCY8 EDNRA	2.67e-05	179	87	5	bfc226bcf0b93525992344f968268a261d86fcbf
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_B-B_atypical-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	ZNF765 ZNF28 CCNB1IP1 RFC3 DMXL1	2.67e-05	179	87	5	5be883d7d0be3180bb9844e4a757f0dd247294e4
ToppCell	droplet-Lung-LUNG-30m-Mesenchymal-Pericyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RNF150 TRPC1 SCN5A ADCY8 EDNRA	2.67e-05	179	87	5	36ad18f52e175ab636ceaa3be81212fa362c96c1
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STMN2 ATP13A3 C12orf60 SLC12A7 DKK2	2.75e-05	180	87	5	baa5825e6ce23a98d9c21d024a4b0ab8ba353d0c
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STMN2 ATP13A3 C12orf60 SLC12A7 DKK2	2.75e-05	180	87	5	2d608b9394d28d19cfc85c6ac94003d5177c8a92
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STMN2 ATP13A3 C12orf60 SLC12A7 DKK2	2.75e-05	180	87	5	0f9b27054358c4737eed06c8ea01987cccc3cb55
ToppCell	Hippocampus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cspg5_(Cspg5)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	FBP1 SPINK2 MC5R TAFA4	2.81e-05	89	87	4	b66575739cb5b89234bbb8a3ea2f244e0bd19cff
ToppCell	Hippocampus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cspg5_(Cspg5)-\|Hippocampus / BrainAtlas - Mouse McCarroll V32	FBP1 SPINK2 MC5R TAFA4	2.81e-05	89	87	4	26f01e8530b313dd5e95ea6c20fa362e34b9ed24
ToppCell	facs-Marrow-Granulocytes-3m-Lymphocytic-mature_alpha-beta_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CTNNAL1 CCN1 ATP13A3 CHM ATP6V0A2	2.82e-05	181	87	5	41969fe4d94ee77b12ecde32170aaf0b13e49644
ToppCell	facs-Marrow-Granulocytes-3m-Lymphocytic-BM_CD8_+_CD4_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CTNNAL1 CCN1 ATP13A3 CHM ATP6V0A2	2.82e-05	181	87	5	3f50e61dc2a52d71a5801584617607e6246adcf2
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Neuronal-neurons_B-Branch_B1_(eMN)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FBP1 SCN2A SCN5A SCN9A STMN2	2.82e-05	181	87	5	7f99002a6411117cc2361334c7c9228e20c574b4
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ASPM TAFA4 ADCY8	2.97e-05	183	87	5	04d3cc76038b8192c915f1c08c3e26f2ad3b3779
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L5-6_SST_ISOC1\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ADCY8 DKK2 MS4A10	2.97e-05	183	87	5	7961e05c6e9964da159059c6bfb4f7e7e14308c2
ToppCell	wk_15-18-Epithelial-Proximal_epithelial-intermediate_neuroendocrine\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	NOL4 DRD2 INHBB STMN2 RFX6	3.05e-05	184	87	5	9e5f98f9113e5e38bdadba6d9d2c346177fb35fe
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LHX1 STXBP1 RGS7BP SCN2A STMN2	3.05e-05	184	87	5	7d9bcdaff8cbea4c50ab7db0f8e01f6bbd0ef593
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SAT1 KIF26B ASPM TAFA4 ADCY8	3.21e-05	186	87	5	6379609b7ace80683f5754b16aa77f11b43766ae
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ASPM TAFA4 ADCY8	3.30e-05	187	87	5	d413fb4b1531b297af5012a392b88128510c2de8
ToppCell	facs-Lung-3m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STMN2 HRH1 ATP13A3 SLC12A7 DKK2	3.30e-05	187	87	5	7170694a1b86fe8d84d96c880ffe57af09bdc026
ToppCell	COVID-19-lung-Artery_EC\|lung / Disease (COVID-19 only), tissue and cell type	CTNNAL1 HRH1 PDE10A RFC3 DKK2	3.38e-05	188	87	5	eecd7482b3c97d7f49993cb17edfab30c61232fc
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	LHX1 RNF150 SAT1 IL1RAPL2 SCN2A	3.38e-05	188	87	5	bc089cd73d283ed7d2ecbb3936673b4edc89f666
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ASPM TAFA4 ADCY8	3.38e-05	188	87	5	8de5a07301f9b5984680c873e5a92395b5ed3dd3
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LHX1 RNF150 SAT1 IL1RAPL2 SCN2A	3.47e-05	189	87	5	977a813e5d7a5a561c1fced2bbf21c20056b88d8
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	INHBB KIF26B ADCY8 DKK2 EDNRA	3.47e-05	189	87	5	06c44746fa4f02e6e2b3b635cdf2d8dfef3754d3
ToppCell	PBMC-Mild-cDC_12\|Mild / Compartment, Disease Groups and Clusters	CTNNAL1 SPINK2 ASPM CDC6 RFC3	3.47e-05	189	87	5	946c95d2ecc36b241f58e8c4ad6455fe47c762fa
ToppCell	COVID-19-Heart-Macrophage\|COVID-19 / Disease (COVID-19 only), tissue and cell type	RNF150 CYRIA SCN9A HRH1 ALOX5	3.47e-05	189	87	5	2586f4088721c5debec86c2b211b739fd33713eb
ToppCell	COVID-19-lung-Artery_EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CTNNAL1 HRH1 PDE10A RFC3 DKK2	3.56e-05	190	87	5	07b675befcd1d0a9c90cb17b5d22323468325d51
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ASPM TAFA4 ADCY8	3.56e-05	190	87	5	305fbef734c350cfbf786ca7ff6e07093aab56ea
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SAT1 KIF26B ASPM TAFA4 ADCY8	3.56e-05	190	87	5	8c9c230a509afaeee50644153974a5642b01a2b8
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ASPM TAFA4 ADCY8	3.56e-05	190	87	5	0acf1d5da68db449d8c9e70519a236ce825f9d11
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ASPM TAFA4 ADCY8	3.56e-05	190	87	5	e58e4b6fbeb4368f738adac67ec10879c0966f0f
ToppCell	ILEUM-non-inflamed-(8)_Activated_fibroblasts\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	STXBP1 CCN1 ASPM STMN2 HEATR3	3.56e-05	190	87	5	39fa110d19c97c7cac99f5fb91b26bc08e2f3b42
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LHX1 RNF150 SAT1 IL1RAPL2 SCN2A	3.56e-05	190	87	5	e252e925600e6457fa6e362a55217f4cffa75cdb
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	INHBB KIF26B ADCY8 DKK2 EDNRA	3.65e-05	191	87	5	de54dab85db70f847de75b3b6d7667a0e13b9bfb
ToppCell	Entopeduncular-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	LHX1 PTCHD1 SCN2A STMN2 CYP4X1	3.65e-05	191	87	5	5d24022cec293bc8d9e978ae99a109e660bb8f83
ToppCell	Entopeduncular-Neuronal-Inhibitory\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	LHX1 PTCHD1 SCN2A STMN2 CYP4X1	3.65e-05	191	87	5	73dae4cdea86aec62393ad7303dc7375a6b3fc86
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B SCN9A ADCY8 DKK2 EDNRA	3.74e-05	192	87	5	dc40ef2341e5d6a6d479f140e023fe1bf687928d
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	INHBB KIF26B ADCY8 DKK2 EDNRA	3.83e-05	193	87	5	2c15186d15545804cc262da9137ab825609d4b2c
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	ZNF845 ATR N4BP2 SBF2 AQR	3.83e-05	193	87	5	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCell	Control-Endothelial-Endothelial\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CTNNAL1 RGS7BP SBF2 SCN9A HRH1	3.83e-05	193	87	5	aff0649c73c634bc6ff0dc7759b4693a9236bf05
ToppCell	Control-Endothelial\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CTNNAL1 RGS7BP SBF2 SCN9A HRH1	3.83e-05	193	87	5	c5f9fe03e64c211d4bcd4959e5b32f14841e336a
ToppCell	3'-GW_trimst-2-SmallIntestine-Neuronal-neurons_A\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FBP1 SCN2A SCN5A SCN9A STMN2	3.83e-05	193	87	5	8851275bcf4ecd6e87a91c8784fc5d76d246ff3b
ToppCell	COPD-Myeloid-ncMonocyte\|COPD / Disease state, Lineage and Cell class	CYRIA SAT1 XPO6 SBF2 HEATR3	3.83e-05	193	87	5	936ca95995599356b794fba32bfd82d8de339365
ToppCell	COPD-Myeloid\|COPD / Disease state, Lineage and Cell class	CYRIA FBP1 SAT1 SBF2 ALOX5	3.83e-05	193	87	5	f58552e286aa27e592497ad78776f58f8ee09841
ToppCell	Brain_organoid-organoid_Paulsen_bioRxiv-1_mon-Neuronal-Cortical_hem\|1_mon / Sample Type, Dataset, Time_group, and Cell type.	SAT1 CCN1 CALU EDNRA FOXJ1	3.93e-05	194	87	5	6f32422e1c079a2fbf0ab568e6cb8365fd627d9a
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Neuronal-neurons_B\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FBP1 SCN2A SCN5A SCN9A STMN2	3.93e-05	194	87	5	15224fb3e7ca5bd1fb8c41f8275842f737014095
ToppCell	343B-Endothelial_cells-Endothelial-B_(Artery)\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	CTNNAL1 SAT1 CCN1 ATP13A3 DKK2	3.93e-05	194	87	5	582db7f7fa9aa08027ae18ed607945b5d1dc908a
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	KIF26B ASPM CCDC150 CDC6 RFC3	3.93e-05	194	87	5	590a9d4f054e6a3685daf752c9354650fcc7d18a
ToppCell	343B-Endothelial_cells-Endothelial-B_(Artery)-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	CTNNAL1 SAT1 CCN1 ATP13A3 DKK2	3.93e-05	194	87	5	bda89111386398a072b70e8153b2a762298a047a
ToppCell	IPF-Myeloid\|IPF / Disease state, Lineage and Cell class	CYRIA FBP1 SAT1 SBF2 ALOX5	4.02e-05	195	87	5	fdeb958aeaa00f3fc25c4e59efbbc6f4a572c9ce
ToppCell	COVID-19-Myeloid-Transitioning_MDM\|COVID-19 / group, cell type (main and fine annotations)	CYRIA SAT1 SBF2 ATP13A3 ALOX5	4.12e-05	196	87	5	4929cfed1f150c1fde4d79cb49895c2ea467a18f
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FBP1 SAT1 ATP13A3 CCL20 ALOX5	4.12e-05	196	87	5	a44a648bf209ce037bfc7b3adfcb220aab60728c
ToppCell	Severe\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	CTNNAL1 CALU EIF4G1 ASPM CDC6	4.22e-05	197	87	5	df3f58b58f82c42c65b0a09c054b669b34502037
ToppCell	Healthy-T/NK_proliferative\|World / disease group, cell group and cell class	CCN1 ASPM CCDC150 CDC6 RFC3	4.22e-05	197	87	5	e90be1e7e02f736b6aab14010a912b592d6f1e80
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_hypoxia\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FBP1 SAT1 ATP13A3 CCL20 ALOX5	4.33e-05	198	87	5	dc59442e6a5127d3071a036c206732a21e456a17
ToppCell	COVID-19-Myeloid\|COVID-19 / group, cell type (main and fine annotations)	CYRIA FBP1 SAT1 SBF2 ALOX5	4.33e-05	198	87	5	33f0a919188a67d2a876b52c61a1cec2c9747969
ToppCell	Non-neuronal-Dividing-Radial_Glia-vRG-11\|World / Primary Cells by Cluster	CTNNAL1 CCN1 ASPM CDC6 RFC3	4.33e-05	198	87	5	672c6faeed54e1397e12c0aac1a5cbd19c684f06
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Duct\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RNF150 DRD2 SAT1 CYP4X1 CCL20	4.43e-05	199	87	5	527aae1d9d37a50deefc01fc0c064a53673681bd
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CYRIA FBP1 SAT1 ATP13A3 CCL20	4.43e-05	199	87	5	880ba91ccecc6633f6daba7822d9200548a8632f
ToppCell	medial-Endothelial-Artery\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CTNNAL1 INHBB HRH1 PDE10A DKK2	4.43e-05	199	87	5	341c0be18bec66f4cc8bda232dce54edb34b9cda
ToppCell	distal-Endothelial-Bronchial_Vessel_2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CTNNAL1 CCN1 HRH1 RFC3 DKK2	4.43e-05	199	87	5	bd9090c13a38a35d50f676fdf11b68eec1340bd3
ToppCell	(06)_OLFM4+\|World / shred by cell type by condition	SAT1 PDE10A SLC12A7 TRIM38 ALOX5	4.43e-05	199	87	5	c773b9180dbfec9c19d4098dd43332e6f6050372
ToppCell	medial-2-Endothelial-Artery\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CTNNAL1 INHBB HRH1 PDE10A DKK2	4.43e-05	199	87	5	53c17c0493f82351a039bc64def191311e0f4951
ToppCell	medial-Endothelial-Artery-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CTNNAL1 INHBB HRH1 PDE10A DKK2	4.43e-05	199	87	5	c455f5a2802f2ec6f0e24266de1aaf3203ca8c78
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intravascular\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RNF150 CYRIA SCN9A HRH1 ALOX5	4.54e-05	200	87	5	179afc4bee7a2fd85a3b5dadf32544a63807c164
ToppCell	390C-Endothelial_cells-Endothelial-B_(Artery)-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	CTNNAL1 CCN1 HRH1 ATP13A3 DKK2	4.54e-05	200	87	5	c32ad15dede3f879007c0b856f2fed1f5b058103
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)\|Neuronal / cells hierarchy compared to all cells using T-Statistic	KIF26B SCN9A ASPM TAFA4 ADCY8	4.54e-05	200	87	5	1276bfa911fddada4235e12e3081baa53164574b
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2--L2-4\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SAT1 KIF26B SCN9A TAFA4 ADCY8	4.54e-05	200	87	5	c65e6336725856c4b5f6aeba1cf86a23ec815d34
ToppCell	Severe-Developping_Plasmablast\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	CTNNAL1 CALU EIF4G1 ASPM CDC6	4.54e-05	200	87	5	6d0cd00e52568d23597cc2a4059bd967d7d2dab5
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW09-Neuronal-Cortical_neuron\|GW09 / Sample Type, Dataset, Time_group, and Cell type.	NOL4 CYRIA STXBP1 SCN2A STMN2	4.54e-05	200	87	5	44bc4d6616fc8d0ad8498e56125939034e8cff01
ToppCell	390C-Endothelial_cells-Endothelial-B_(Artery)\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	CTNNAL1 CCN1 HRH1 ATP13A3 DKK2	4.54e-05	200	87	5	8a2c6c53a39fab86750526083f7254b7413b29af
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal\|6m / Sample Type, Dataset, Time_group, and Cell type.	NOL4 CYRIA STXBP1 SCN2A STMN2	4.54e-05	200	87	5	cedbc47b1defb5973cf7ab6baaa2d6f2fd481f88
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal-Cortical_neuron\|6m / Sample Type, Dataset, Time_group, and Cell type.	NOL4 CYRIA STXBP1 SCN2A STMN2	4.54e-05	200	87	5	6f7ff0533339fcc9d316f2c77334a79c1409ec4f
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-1m-Stem_cells\|1m / Sample Type, Dataset, Time_group, and Cell type.	CTNNAL1 ASPM TAFA4 CDC6 RFC3	4.54e-05	200	87	5	13636463e44a99cd886926340bfb35880f95cca6
ToppCell	Severe-Developping_Plasmablast\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	CTNNAL1 CALU EIF4G1 ASPM CDC6	4.54e-05	200	87	5	80639e0d2ddaae36ac7634a4f03e8809af7316e3
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-1m-Stem_cells-Neuroepithelial_cell\|1m / Sample Type, Dataset, Time_group, and Cell type.	CTNNAL1 ASPM TAFA4 CDC6 RFC3	4.54e-05	200	87	5	2a3874634cc4357a64ef9fd4a6bbdfd84236ebac
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SAT1 KIF26B SCN9A TAFA4 ADCY8	4.54e-05	200	87	5	117a25b3b9cdbc2e198381350a8362bee25e82e7
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SAT1 KIF26B SCN9A TAFA4 ADCY8	4.54e-05	200	87	5	d459e51507bf26865e6e7e04411379ec82a3edf8
ToppCell	Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_1-Sox4-POLYDENDROCYTE_(Neurogenesis.Sox4.Hist1h2al)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	DRD3 SPINK2 ASPM CDC6	1.09e-04	126	87	4	6072996987f7b05949adb86c9433e3302c4441d2
ToppCell	368C-Fibroblasts-Fibroblast-F\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	AADACL2 SCN5A RFC3 ARMH3	2.08e-04	149	87	4	f53151d9e5e724a61be0ee6a8c740d1990f28d5f
ToppCell	368C-Fibroblasts-Fibroblast-F-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	AADACL2 SCN5A RFC3 ARMH3	2.08e-04	149	87	4	9286bc56ff2e245630537a0bda5f1a1e17be863a
ToppCell	Fetal_29-31_weeks-Endothelial-endothelial_cell_of_artery-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SCN2A PDE10A RFC3 DKK2	2.19e-04	151	87	4	3b4c57bad61e17a573e6f8dc6b917fba5fd56c43
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	LHX1 SCN2A STMN2 DKK2	2.30e-04	153	87	4	79c4f4ccdc8249c8461075c73491bc3b2d13344a
ToppCell	E15.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ASXL1 INHBB STMN2 ARMH3	2.36e-04	154	87	4	e65e4636646164610f33f7bbac0d879a3ea55986
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-mature_enterocytic-Paneth\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	AXDND1 IFT172 CCL20 DKK2	2.73e-04	160	87	4	6005948e400e781cdb876ba350b3ec8991e3945f
ToppCell	10x5'v1-week_17-19-Hematopoietic-HSC/MPP_and_pro-HSC/MPP\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SPINK2 TRPC1 SCN5A FOXJ1	2.79e-04	161	87	4	aee74a2e7a8acd2950341963f1c04b59c7862183
Drug	isofloxythepin	DRD2 DRD3 HRH1	1.74e-06	7	85	3	CID000115193
Drug	CTK4D3724	DRD2 DRD3 HRH1	4.15e-06	9	85	3	CID000128010
Drug	AC1OCEMN	DRD2 DRD3 HRH1	4.15e-06	9	85	3	CID006917765
Drug	tegafur/uracil	NLRP9 CCL20 ATP6V0A2 NLRP8	6.82e-06	33	85	4	CID000104747
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; HL60; HT_HG-U133A	CUL3 STXBP1 RAB3GAP2 ARMH3 HEATR3 DMXL1 ATP6V0A2	8.24e-06	194	85	7	1264_DN
Drug	Chlorprothixene	DRD2 DRD3 HRH1	1.08e-05	12	85	3	DB01239
Drug	Sulpiride	DRD2 DRD3	1.38e-05	2	85	2	DB00391
Drug	N-n-propyl-N-phenylethyl-4(3-hydroxyphenyl)ethylamine hydrochloride	DRD2 DRD3	1.38e-05	2	85	2	ctd:C016868
Drug	Ranolazine	SCN5A SCN9A	1.38e-05	2	85	2	DB00243
Drug	5-methoxy-1-methyl-2-(n-propylamino)tetralin	DRD2 DRD3	1.38e-05	2	85	2	ctd:C051171
Drug	CGS 15855A	DRD2 DRD3	1.38e-05	2	85	2	ctd:C051347
Drug	(5,6-dimethoxyindan-2-yl)dipropylamine	DRD2 DRD3	1.38e-05	2	85	2	ctd:C086335
Drug	Domperidone	DRD2 DRD3	1.38e-05	2	85	2	DB01184
Drug	UH 232	DRD2 DRD3	1.38e-05	2	85	2	ctd:C045971
Drug	4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrzolo(3,4-g)quinoline	DRD2 DRD3	1.38e-05	2	85	2	ctd:C416545
Drug	3-(3-cyanophenyl)-N-n-propylpiperidine	DRD2 DRD3	1.38e-05	2	85	2	ctd:C094012
Drug	iodosulpride	DRD2 DRD3	1.38e-05	2	85	2	ctd:C045105
Drug	fluoroclebopride	DRD2 DRD3	1.38e-05	2	85	2	ctd:C083673
Drug	GR 218231	DRD2 DRD3	1.38e-05	2	85	2	ctd:C408390
Drug	efletirizine	HRH1 ALOX5	1.38e-05	2	85	2	ctd:C121361
Drug	N-(4-(2-(4-(3-cyano-5-trifluoromethylphenyl)piperazin-1-yl)ethyl)cyclohexyl)-3-pyridinesulfonic amide	DRD2 DRD3	1.38e-05	2	85	2	ctd:C539157
Drug	Piribedil	DRD2 DRD3	1.38e-05	2	85	2	ctd:D010891
Drug	AC1L31N6	DRD2 DRD3	1.38e-05	2	85	2	CID000132830
Drug	diphenidol	DRD2 DRD3 HRH1	1.40e-05	13	85	3	CID000003055
Drug	Risperidone	DRD2 DRD3 HRH1	1.77e-05	14	85	3	DB00734
Drug	DB08666	SCN2A SCN5A EIF4G1 HRH1 CCL20	2.21e-05	90	85	5	CID011840988
Drug	A 86929	DRD2 DRD3 EDNRA	2.21e-05	15	85	3	ctd:C095427
Drug	AC1L2AAS	DRD2 DRD3 ADCY8	2.21e-05	15	85	3	CID000068714
Drug	fluphenazine	DRD2 DRD3 SCN9A HRH1 ADCY8	2.72e-05	94	85	5	CID000003372
Drug	Paliperidone	DRD2 DRD3 HRH1	3.29e-05	17	85	3	DB01267
Drug	Zonisamide	SCN2A SCN5A SCN9A	3.29e-05	17	85	3	DB00909
Drug	PGW5 compound	DRD2 DRD3 HRH1	3.29e-05	17	85	3	ctd:C000593032
Drug	AC1Q7BEJ	DRD2 DRD3 HRH1 ADCY8	3.65e-05	50	85	4	CID000001224
Drug	moricizine	SCN5A SCN9A HRH1	3.93e-05	18	85	3	CID000034632
Drug	(1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate)	DRD2 DRD3	4.12e-05	3	85	2	ctd:C461261
Drug	DP-6OH-3CA	DRD2 DRD3	4.12e-05	3	85	2	CID000086146
Drug	Neuriplege	DRD2 DRD3	4.12e-05	3	85	2	CID000065750
Drug	7-(N,N-dipropylamino)-5,6,7,8-tetrahydronaphtho(2,3-b)dihydro-2,3-furan	DRD2 DRD3	4.12e-05	3	85	2	ctd:C090812
Drug	7-hydroxy-2-N,N-dipropylaminotetralin	DRD2 DRD3	4.12e-05	3	85	2	ctd:C031349
Drug	3-N-methylspiperone	DRD2 DRD3	4.12e-05	3	85	2	ctd:C039167
Drug	quinelorane	DRD2 DRD3	4.12e-05	3	85	2	ctd:C047726
Drug	FLA908	DRD2 DRD3	4.12e-05	3	85	2	CID000129516
Drug	SB-277011	DRD2 DRD3	4.12e-05	3	85	2	CID005311096
Drug	DCHAPS	DRD2 DRD3	4.12e-05	3	85	2	CID000129392
Drug	nafadotride	DRD2 DRD3	4.12e-05	3	85	2	ctd:C097285
Drug	BP 897	DRD2 DRD3	4.12e-05	3	85	2	ctd:C120565
Drug	iodoethylspiperone	DRD2 DRD3	4.12e-05	3	85	2	CID000131222
Drug	Ro 41-9067	DRD2 DRD3 ADCY8	4.66e-05	19	85	3	CID000125800
Drug	Methotrimeprazine	DRD2 DRD3 HRH1	4.66e-05	19	85	3	DB01403
Drug	RP 62203	DRD2 DRD3 HRH1	4.66e-05	19	85	3	CID000060785
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HG-U133A	CYRIA STXBP1 ATR CALU CCL20 DMXL1	7.02e-05	186	85	6	1612_UP
Drug	NSC186061	DRD2 DRD3 HRH1 ALOX5 ADCY8	8.09e-05	118	85	5	CID000004163
Drug	metopimazine	DRD2 HRH1	8.22e-05	4	85	2	CID000026388
Drug	Lidocaine	SCN5A SCN9A	8.22e-05	4	85	2	DB00281
Drug	clofluperol	DRD2 DRD3	8.22e-05	4	85	2	CID000025293
Drug	Pimozide	DRD2 DRD3	8.22e-05	4	85	2	DB01100
Drug	NCQ-469	DRD2 DRD3	8.22e-05	4	85	2	CID000127915
Drug	spectramide	DRD2 DRD3	8.22e-05	4	85	2	CID000130377
Drug	Amisulpride	DRD2 DRD3	8.22e-05	4	85	2	DB06288
Drug	sarizotan	DRD2 DRD3	8.22e-05	4	85	2	ctd:C443959
Drug	Cinnarizine	DRD2 HRH1	8.22e-05	4	85	2	ctd:D002936
Drug	3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol	DRD2 DRD3	8.22e-05	4	85	2	ctd:C062458
Drug	SKF83959	DRD2 DRD3	8.22e-05	4	85	2	CID000133538
Drug	ethacizine	SCN9A HRH1	8.22e-05	4	85	2	CID000107841
Drug	CAS 66104-23-2	DRD2 DRD3 HRH1 ADCY8	9.11e-05	63	85	4	CID000004745
Drug	TL-99	DRD2 DRD3 ADCY8	9.60e-05	24	85	3	CID000122132
Drug	Anabasine [494-52-0]; Up 200; 24.6uM; HL60; HT_HG-U133A	CYRIA SPAM1 FBP1 IL1RAPL2 TRPC1 ALOX5	9.64e-05	197	85	6	2512_UP
Drug	S-(-)-Lisuride	DRD2 DRD3 HRH1 ADCY8	1.03e-04	65	85	4	CID000003938
Drug	Naringin hydrate [11032-30-7]; Up 200; 6.6uM; PC3; HT_HG-U133A	LHX1 DRD2 TRPC1 PDE10A GPR45 EDNRA	1.05e-04	200	85	6	4605_UP
Drug	Olanzapine	DRD2 DRD3 HRH1	1.09e-04	25	85	3	DB00334
Drug	Ziprasidone	DRD2 DRD3 HRH1	1.09e-04	25	85	3	DB00246
Drug	Aripiprazole	DRD2 DRD3 HRH1	1.09e-04	25	85	3	DB01238
Drug	hydroxamates	DRD2 DRD3 HRH1	1.09e-04	25	85	3	CID000033630
Drug	lamotrigine	DRD2 SCN2A HRH1	1.09e-04	25	85	3	ctd:C047781
Drug	N-n-propylnorapomorphine	DRD2 DRD3 ADCY8	1.09e-04	25	85	3	CID000030137
Drug	Clozapine	DRD2 DRD3 HRH1	1.23e-04	26	85	3	DB00363
Drug	Quetiapine	DRD2 DRD3 HRH1	1.23e-04	26	85	3	DB01224
Drug	T15550	DRD2 DRD3 HRH1	1.23e-04	26	85	3	CID000005454
Drug	cyamemazine	DRD2 DRD3 HRH1	1.23e-04	26	85	3	CID000062865
Drug	tyramine	DRD2 DRD3 HRH1 ADCY8 EDNRA	1.28e-04	130	85	5	CID000005610
Drug	GBR 12909	DRD2 DRD3 SCN9A HRH1	1.30e-04	69	85	4	CID000003455
Drug	Haloperidol	DRD2 DRD3	1.37e-04	5	85	2	DB00502
Drug	Remoxipride	DRD2 DRD3	1.37e-04	5	85	2	DB00409
Drug	tilozepine	DRD2 DRD3	1.37e-04	5	85	2	CID000172286
Drug	SKF 77434	DRD2 DRD3	1.37e-04	5	85	2	CID000001241
Drug	Levodopa	DRD2 DRD3	1.37e-04	5	85	2	DB01235
Drug	moperone	DRD2 DRD3	1.37e-04	5	85	2	CID000004249
Drug	dazopride	DRD2 DRD3	1.37e-04	5	85	2	CID000054801
Drug	haloperidol hemisuccinate	DRD2 DRD3	1.37e-04	5	85	2	CID000088143
Drug	azapride	DRD2 DRD3	1.37e-04	5	85	2	CID003036441
Drug	2-di-n-propylaminoindan	DRD2 DRD3	1.37e-04	5	85	2	CID000130402
Drug	mezilamine	DRD2 DRD3	1.37e-04	5	85	2	CID000068678
Drug	NO 756	DRD2 DRD3	1.37e-04	5	85	2	CID000129967
Drug	SKF85174	DRD2 DRD3	1.37e-04	5	85	2	CID000132435
Drug	pipotiazine	DRD2 DRD3	1.37e-04	5	85	2	CID000062867
Drug	3-iodobenzamide	DRD2 DRD3	1.37e-04	5	85	2	CID000202425
Drug	declopramide	DRD2 DRD3	1.37e-04	5	85	2	CID000070177
Drug	tefludazine	DRD2 DRD3	1.37e-04	5	85	2	CID000071240
Drug	rotigotine	DRD2 DRD3	1.37e-04	5	85	2	ctd:C047508
Drug	piquindone	DRD2 DRD3	1.37e-04	5	85	2	CID000121903
Disease	generalized epilepsy with febrile seizures plus 2 (implicated_via_orthology)	SCN2A SCN5A SCN9A	2.73e-06	10	85	3	DOID:0111294 (implicated_via_orthology)
Disease	Dravet syndrome (implicated_via_orthology)	SCN2A SCN5A SCN9A	2.73e-06	10	85	3	DOID:0080422 (implicated_via_orthology)
Disease	nicotine dependence (implicated_via_orthology)	DRD2 DRD3 TRPC1	4.98e-06	12	85	3	DOID:0050742 (implicated_via_orthology)
Disease	generalized epilepsy with febrile seizures plus (implicated_via_orthology)	SCN2A SCN5A SCN9A	4.98e-06	12	85	3	DOID:0060170 (implicated_via_orthology)
Disease	Infantile Severe Myoclonic Epilepsy	STXBP1 SCN2A SCN9A	6.46e-06	13	85	3	C0751122
Disease	Disruptive, Impulse Control, and Conduct Disorders	DRD2 DRD3	2.46e-05	3	85	2	C0021122
Disease	Intermittent Explosive Disorder	DRD2 DRD3	2.46e-05	3	85	2	C0021776
Disease	facial height measurement	CYRIA ZNF28 KIAA0825 RAB3GAP2 SCN5A	5.79e-05	142	85	5	EFO_0007856
Disease	heroin dependence (biomarker_via_orthology)	DRD2 DRD3	8.15e-05	5	85	2	DOID:9976 (biomarker_via_orthology)
Disease	response to selective serotonin reuptake inhibitor	PTCHD1 MTMR12 KIF26B STMN2	9.45e-05	82	85	4	EFO_0005658
Disease	Hyperkinesia, Generalized	DRD2 DRD3 ADCY8	1.08e-04	32	85	3	C0751217
Disease	Hyperkinesia	DRD2 DRD3 ADCY8	1.08e-04	32	85	3	C3887506
Disease	epilepsy (implicated_via_orthology)	SCN2A SBF2 SCN5A SCN9A SLC12A7	1.11e-04	163	85	5	DOID:1826 (implicated_via_orthology)
Disease	Antihypertensive use measurement	KIAA0825 SBF2 PDE10A RMC1 ADCY8 EDNRA	1.20e-04	265	85	6	EFO_0009927
Disease	atrioventricular septal defect (implicated_via_orthology)	CCN1 IFT172	1.71e-04	7	85	2	DOID:0050651 (implicated_via_orthology)
Disease	Early Childhood Epilepsy, Myoclonic	STXBP1 SCN9A	2.27e-04	8	85	2	C0393695
Disease	Idiopathic Myoclonic Epilepsy	STXBP1 SCN9A	2.27e-04	8	85	2	C0338478
Disease	Symptomatic Myoclonic Epilepsy	STXBP1 SCN9A	2.27e-04	8	85	2	C0338479
Disease	Myoclonic Encephalopathy	STXBP1 SCN9A	2.27e-04	8	85	2	C0438414
Disease	Benign Infantile Myoclonic Epilepsy	STXBP1 SCN9A	2.27e-04	8	85	2	C0751120
Disease	Myoclonic Absence Epilepsy	STXBP1 SCN9A	2.27e-04	8	85	2	C0393703
Disease	Pruritus	SCN9A HRH1	2.27e-04	8	85	2	C0033774
Disease	neuroticism measurement, cognitive function measurement	ASXL1 DRD2 KIAA0825 CALU N4BP2 SCN2A RMC1 ADCY8	2.30e-04	566	85	8	EFO_0007660, EFO_0008354
Disease	Recurrent depression	DRD2 DRD3	2.91e-04	9	85	2	C0221480
Disease	Myoclonic Epilepsy	STXBP1 SCN9A	2.91e-04	9	85	2	C0014550
Disease	Generalized Epilepsy with Febrile Seizures Plus	SCN2A SCN9A	2.91e-04	9	85	2	C3502809
Disease	myelodysplastic syndrome	TAF2 TAFA4	3.64e-04	10	85	2	EFO_0000198
Disease	Epilepsy, Myoclonic, Infantile	STXBP1 SCN9A	3.64e-04	10	85	2	C0917800
Disease	Delirium	DRD2 DRD3	3.64e-04	10	85	2	C0011206
Disease	Myoclonic Astatic Epilepsy	STXBP1 SCN9A	4.44e-04	11	85	2	C0393702
Disease	Lenticulostriate Disorders	DRD2 DRD3	5.31e-04	12	85	2	C0750951
Disease	Extrapyramidal Disorders	DRD2 DRD3	5.31e-04	12	85	2	C0015371
Disease	Basal Ganglia Diseases	DRD2 DRD3	5.31e-04	12	85	2	C0004782
Disease	Withdrawal Symptoms	DRD2 HRH1 ADCY8	6.35e-04	58	85	3	C0087169
Disease	Drug Withdrawal Symptoms	DRD2 HRH1 ADCY8	6.35e-04	58	85	3	C0086189
Disease	Substance Withdrawal Syndrome	DRD2 HRH1 ADCY8	6.35e-04	58	85	3	C0038587
Disease	Dyskinesia, Drug-Induced	DRD2 DRD3	8.40e-04	15	85	2	C0013386
Disease	Dyskinesia, Medication-Induced	DRD2 DRD3	8.40e-04	15	85	2	C0751088
Disease	Early infantile epileptic encephalopathy with suppression bursts	STXBP1 SCN2A	9.59e-04	16	85	2	C0393706
Disease	Alcoholic Intoxication, Chronic	DRD2 DRD3 SAT1 PDE10A DKK2	1.08e-03	268	85	5	C0001973
Disease	Parkinson's disease (implicated_via_orthology)	DRD2 DRD3 EIF4G1 ATP13A3	1.12e-03	157	85	4	DOID:14330 (implicated_via_orthology)
Disease	portal hypertension (implicated_via_orthology)	ALOX5 EDNRA	1.36e-03	19	85	2	DOID:10762 (implicated_via_orthology)
Disease	Chronic myeloproliferative disorder	ATR CDC6	1.36e-03	19	85	2	C1292778
Disease	Mood Disorders	DRD2 DRD3 SAT1 ADCY8	1.43e-03	168	85	4	C0525045
Disease	Infiltrating duct carcinoma of female breast	SMG1 ATR	1.66e-03	21	85	2	C3165106
Disease	cigarettes per day measurement	ASXL1 DRD2 STXBP1 SCN2A RMC1 ADCY8	1.68e-03	438	85	6	EFO_0006525
Disease	Seckel syndrome	ATR CDC6	1.82e-03	22	85	2	C0265202
Disease	anxiety disorder (implicated_via_orthology)	SCN2A SCN9A	1.82e-03	22	85	2	DOID:2030 (implicated_via_orthology)
Disease	smoking status measurement	CUL3 NOL4 RNF150 GAPVD1 DRD2 SPINK2 RAB3GAP2 SCN2A RMC1 ADCY8	1.83e-03	1160	85	10	EFO_0006527
Disease	heel bone mineral density, urate measurement	NPY4R2 NPY4R PDE10A DKK2	1.92e-03	182	85	4	EFO_0004531, EFO_0009270
Disease	Etat Marbre	DRD2 DRD3	1.99e-03	23	85	2	C0266487
Disease	West Syndrome	STXBP1 SCN2A	2.17e-03	24	85	2	C0037769
Disease	nephrotic syndrome (implicated_via_orthology)	GAPVD1 ALOX5	2.17e-03	24	85	2	DOID:1184 (implicated_via_orthology)
Disease	traumatic brain injury (biomarker_via_orthology)	DRD2 PDE10A	2.17e-03	24	85	2	DOID:0081292 (biomarker_via_orthology)
Disease	Neurodevelopmental Disorders	CUL3 STXBP1 SCN2A	2.48e-03	93	85	3	C1535926
Disease	smoking cessation	CUL3 ASXL1 DRD2 STXBP1 SCN2A	2.51e-03	325	85	5	EFO_0004319
Disease	Bipolar Disorder	DRD2 DRD3 SAT1 SCN2A PDE10A ADCY8	2.58e-03	477	85	6	C0005586

Protein segments in the cluster

Peptide	Gene	Start	Entry
CCVEMGLSMIKTIRY	ADCY8	481	P40145
KTCTFTAMCFENMRI	AADACL2	41	Q6P093
EMLVKSQFVACMATC	ATP13A3	531	Q9H7F0
ETFSKNVMMIQSCKC	CCN1	341	O00622
CMKNLMESLDSLLCA	ARMH3	136	Q5T2E6
CCCYQSKSLMTSVPM	EDNRA	386	P25101
MDLRQFLMCLSLCTA	CALU	1	O43852
SSKAYLMSICCMVNE	AQR	86	O60306
SCDMCELARNSVLMS	AMPD2	791	Q01433
MAALMRSKDSSCCLL	DKK2	1	Q9UBU2
SLCKSIMMYACTKNV	DMXL1	541	Q9Y485
MAYMCTSQQTCKVPL	ASPM	401	Q8IZT6
SISLQCACSLKAMIM	ASXL1	1501	Q8IXJ9
ELCSSTMTCMKGTYL	CHM	491	P24386
CLEMYTTEMLKSICL	RGS7BP	131	Q6MZT1
VDTLIMMYKTHCQCI	RFX6	261	Q8HWS3
SCKELADLMTRCMNY	JAK1	816	P23458
ICCLHTMLSLLSKMK	RAB3GAP2	791	Q9H2M9
DCLSTMTSVCKVMLE	CYRIA	221	Q9H0Q0
ALMMALVVLSCKSSC	IFNA14	6	P01570
ICMCLKSIMGDQTSI	KIAA0825	1051	Q8IV33
ETLCKMSAFIQCMSV	NPY4R	111	P50391
DLCCLISSLVQLMMD	MTMR12	396	Q9C0I1
IIRMMNCTLQDCSSL	SBF2	611	Q86WG5
TSNIFAIMNCDKMCV	NLRP8	101	Q86W28
TSICCQAMASMLRKN	NLRP8	966	Q86W28
CCIPTKLSTMSMLYF	INHBB	371	P09529
CKAHLMMITCFDITS	KIF26B	2091	Q2KJY2
CILRMCSTIMNLLSL	GAPVD1	1396	Q14C86
IGLMMTACDLCSVTK	PDE10A	656	Q9Y233
KMLCLMTNLISLFCV	MS4A10	121	Q96PG2
LNCFTCMMCNKQLST	LHX1	86	P48742
MLCAYMCILNTVRKN	GPR45	211	Q9Y5Y3
MSTYANECTLCMKIR	SPINK2	56	P20155
SCSKTMILNFCSYMQ	IFT172	516	Q9UG01
LVMNMLKSSFATCVL	FBP1	81	P09467
EMQLTSAKCLTYMCR	ARMC8	251	Q8IUR7
LASKIFTCCSIMMKH	ATR	1506	Q13535
ISQCMTPDQLMTLCK	HEATR3	531	Q7Z4Q2
KKCSELSCMLQTVTM	CCDC150	351	Q8NCX0
LEKCTMMLLTASKTC	CTNNAL1	231	Q9UBT7
YLSSCCKGMVTAMAL	AXDND1	761	Q5T1B0
KTMCECMSSYLREQG	CUL3	311	Q13618
LGEMSYTTMCIKETC	CYP4X1	361	Q8N118
YATLICMAMQASKAT	FOXJ1	126	Q92949
FKTIMLNCMSLRTAQ	CDC6	226	Q99741
ANMCRCLMALKVPTT	EIF4G1	816	Q04637
MICISVVASMCSLLA	MC5R	121	P33032
IMELLIMVYACKTSC	PRPSAP2	86	O60256
RSMKSCLLLDNYMET	SPAM1	346	P38567
RMCYLTIKEMSCIAE	COPG1	86	Q9Y678
MMCTASILNLCAISI	DRD2	116	P14416
MSLPNSSCLLEDKMC	HRH1	1	P35367
IVAMCCTCTMLTAIS	SLC12A7	156	Q9Y666
VMMCTASILNLCAIS	DRD3	111	P35462
TMEKYMSTCRLILCC	RFC3	151	P40938
MAMSLIQACCSLALS	RNF150	1	Q9ULK6
LAYVLMVCCKLMSAS	TAFA4	21	Q96LR4
MEEATCSICLSLMTN	TRIM38	11	O00635
MVQRAMKDLTYASLC	ALOX5	436	P09917
TMAILCCSMQDCVRS	PTCHD1	281	Q96NR3
MSACFCLAKIANSMV	TAF2	696	Q6P1X5
CVLRNSTYCMKVSMS	IL1RAPL2	116	Q9NP60
MEMLSSCAISFCKSV	SMG1	1501	Q96Q15
SLFNMLIMCTILTNC	SCN5A	131	Q14524
SLFSMLIMCTILTNC	SCN9A	126	Q15858
KNLSQVAMRCRCSSM	SAT1	111	P21673
LVVDQLSMRMLSSCC	STXBP1	31	P61764
LSMRMLSSCCKMTDI	STXBP1	36	P61764
LSSCCKMTDIMTEGI	STXBP1	41	P61764
VTRFLMSCSECQKRM	NOL4	151	O94818
MCCTKSLLLAALMSV	CCL20	1	P78556
MSLCEDMLLCNYRKC	CCNB1IP1	1	Q9NPC3
LCSKVAMAMCSVVQK	C12orf60	86	Q5U649
CALERLMLMYCCLTS	NLRP9	771	Q7RTR0
LMLMYCCLTSVSCDS	NLRP9	776	Q7RTR0
YRNLVSLDISSKCMM	ZNF845	41	Q96IR2
CCLVHRYLTSMRQKM	TRPC1	736	P48995
CLSLDKVIMEMSTCE	UHRF1BP1L	81	A0JNW5
YRNLVSLDISSKCMM	ZNF320	41	A2RRD8
CKMVILSVCSQMLSE	RMC1	386	Q96DM3
MDKCVCLLTAFSERM	SPATA20	666	Q8TB22
MCTILTNCVFMTMSN	SCN2A	136	Q99250
ETLCKMSAFIQCMSV	NPY4R2	111	P0DQD5
YRNLVSLDISSKCMM	ZNF813	41	Q6ZN06
YRNLVSLDISSKCMM	ZNF888	41	P0CJ79
YRNLVSLDISSKCMM	ZNF28	41	P17035
YRNLVSLDISSKCMM	ZNF765	41	Q7L2R6
KMKELSMLSLICSCF	STMN2	11	Q93045
LAMSCINELMSKNCV	XPO6	311	Q96QU8
MLNMCSFDVTNKCLI	ATP6V0A2	311	Q9Y487
MLLSEMTCESQTCLS	N4BP2	951	Q86UW6